Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer-Reference-Cited by-同舟云学术

Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer

Published:2020-05 Issue: Volume:149 Page:102927
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Musolino Antonino^ORCID,Boggiani Daniela,Pellegrino Benedetta,Zanoni Daniele,Sikokis Angelica,Missale Gabriele,Silini Enrico Maria,Maglietta Giuseppe,Frassoldati Antonio,Michiara Maria

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference108 articles.

1. Human Epidermal Growth Factor Receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma;Ahmed;J. Clin. Oncol.,2015

2. Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial;Ahmed;J. Immunother. Cancer,2015

3. Progress and challenges in the design and clinical development of antibodies for cancer therapy;Almagro;Front. Immunol.,2018

4. ZW25 effective in HER2-positive cancers;Anon;Cancer Discov.,2019

5. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?;Arnould;Br. J. Cancer,2006

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances from targeted therapy for non‐metastatic HER2‐positive inflammatory breast cancer;Journal of Surgical Oncology;2024-08-05

2. Overcoming Breast Cancer Resistance to Targeted, Chemo-, and Immuno Therapy: Mechanisms and Strategies to Overcome Resistance and Facilitate Drug Development;Interdisciplinary Cancer Research;2024

3. Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016);Journal for ImmunoTherapy of Cancer;2023-11

4. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient’s response to conventional and novel therapies;Journal of Translational Medicine;2023-09-09

5. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies;J TRANSL MED;2023